{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:26:44Z","timestamp":1787668004233,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Suleyman Demirel University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The success of surgical treatment in Primary Hyperparathyroidism (PHPT) depends on the accurate localization of the parathyroid adenoma. Although cervical ultrasonography (USI) and \u2079\u2079\u1d50Tc- Sestamibi scintigraphy are common methods in this context, their diagnostic performance might be limited in small, ectopically located, or biologically atypical lesions. As a novel PET agent targeting integrin \u03b1v\u03b26 (alpha-v beta-6), \u2076\u2078Ga-Trivehexin can image biological processes associated with pathological tissue remodeling. This proof-of-concept study aimed to evaluate the feasibility and potential diagnostic contribution of \u2076\u2078Ga-Trivehexin PET\/CT in detecting parathyroid adenoma in patients with PHPT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, prospective proof-of-concept study included 28 patients who had a biochemical diagnosis of PHPT. All patients underwent neck ultrasound, \u2079\u2079\u1d50Tc-Sestamibi parathyroid scintigraphy, and \u2076\u2078Ga-Trivehexin PET\/CT imaging. Fine Needle Aspiration Biopsy (FNAB) and Parathyroid Hormone (PTH) washout tests were performed for some patients as clinically necessary. Histopathological findings were used as the reference standard in patients who underwent surgery. The agreement between imaging methods was evaluated with Cohen\u2019s Kappa coefficient for exploratory purposes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 64.2% of the patients were female, and the mean age was 56.1\u2009\u00b1\u200911.3 years. \u2079\u2079\u1d50Tc- Sestamibi scintigraphy was found to be positive in 60.7% of the patients, while the positivity rate for \u2076\u2078Ga-Trivehexin PET\/CT was 78.6%. A significant proportion of cases with negative \u2079\u2079\u1d50Tc- Sestamibi scintigraphy showed positive lesions with \u2076\u2078Ga-Trivehexin PET\/CT. Statistically significant, moderate agreement levels were detected in all patients between \u2079\u2079\u1d50Tc-Sestamibi scintigraphy and \u2076\u2078Ga-Trivehexin PET\/CT (kappa\u2009=\u20090.430; p\u2009=\u20090.013). A moderate level of agreement was observed between the two methods in patients with histopathologically confirmed parathyroid adenoma (kappa\u2009=\u20090.429; p\u2009=\u20090.070).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results of this proof-of-concept study imply that \u2076\u2078Ga-Trivehexin PET\/CT may be a feasible and promising imaging method for localizing parathyroid adenomas in patients with primary hyperparathyroidism. It may offer potential contributions as a complementary diagnostic tool,<\/jats:p>\n                    <jats:p>particularly in selected cases where conventional imaging methods are limited. Further large, multicenter studies are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12149-026-02232-x","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:33:44Z","timestamp":1779442424000},"page":"1131-1137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early clinical experience with \u2076\u2078Ga-Trivehexin PET\/CT in parathyroid adenomas: a proof-of- concept imaging study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7724-778X","authenticated-orcid":false,"given":"Mehmet","family":"Erdogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5066-6335","authenticated-orcid":false,"given":"Hakan","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9730-2846","authenticated-orcid":false,"given":"Mustafa","family":"Avc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3456-935X","authenticated-orcid":false,"given":"Zeynep","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8435-3828","authenticated-orcid":false,"given":"Ahmet","family":"Tun\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4009-369X","authenticated-orcid":false,"given":"Sevim S\u00fcreyya","family":"Sengul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"10116","key":"2232_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0140-6736(17)31430-7","volume":"391","author":"JP Bilezikian","year":"2018","unstructured":"Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet. 2018;391(10116):168\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(17)31430-7. (Epub 2017 Sep 17. PMID: 28923463).","journal-title":"Lancet"},{"issue":"23","key":"2232_CR2","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1002\/cncr.28891","volume":"120","author":"GG Callender","year":"2014","unstructured":"Callender GG, Udelsman R. Surgery for primary hyperparathyroidism. Cancer. 2014;120(23):3602\u201316. https:\/\/doi.org\/10.1002\/cncr.28891. (Epub 2014 Jul 9. PMID: 25042934).","journal-title":"Cancer"},{"issue":"2","key":"2232_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.5603\/ep.103003","volume":"76","author":"A Witowska","year":"2025","unstructured":"Witowska A, Cie\u015blewicz M, Suchecka W, Czepczy\u0144ski R, Szczepanek-Parulska E, et al. Contemporary localization diagnostics in primary hyperparathyroidism. review of visualization techniques including ultrasonography, PTH washout, 99mTc-MIBI scintigraphy, and 18F- choline PET. Endokrynol Pol. 2025;76(2):127\u201333. https:\/\/doi.org\/10.5603\/ep.103003.","journal-title":"Endokrynol Pol"},{"issue":"4","key":"2232_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1053\/j.semnuclmed.2005.06.001","volume":"35","author":"CJ Palestro","year":"2005","unstructured":"Palestro CJ, Tomas MB, Tronco GG. Radionuclide imaging of the parathyroid glands. Semin Nucl Med. 2005;35(4):266\u201376. https:\/\/doi.org\/10.1053\/j.semnuclmed.2005.06.001. (PMID: 16150247).","journal-title":"Semin Nucl Med"},{"issue":"9","key":"2232_CR5","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s12149-020-01507-1","volume":"34","author":"L Evangelista","year":"2020","unstructured":"Evangelista L, Ravelli I, Magnani F, Iacobone M, Giraudo C, Camozzi V, et al. 18F-choline PET\/CT and PET\/MRI in primary and recurrent hyperparathyroidism: a systematic review of the literature. Ann Nucl Med. 2020;34(9):601\u201319. https:\/\/doi.org\/10.1007\/s12149-020-01507-1.","journal-title":"Ann Nucl Med"},{"issue":"7","key":"2232_CR6","first-page":"468","volume":"38","author":"P Thakral","year":"2023","unstructured":"Thakral P, Das SS, Dhiman S, Manda D, Virupakshappa CB, Malik D, et al. Validation of in- house kit-like synthesis of 68Ga-Trivehexin and its biodistribution for targeting the integrin \u03b1v\u03b26 expressing tumors. Cancer Biother Radiopharm. 2023;38(7):468\u201374 (Epub 2023 Apr 21. PMID: 37093129).","journal-title":"Cancer Biother Radiopharm"},{"key":"2232_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06750-6","author":"J Rehm","year":"2024","unstructured":"Rehm J, Winzer R, Notni J, Hempel S, Distler M, Folprecht G, et al. Concomitant metastatic head-and-neck cancer and pancreatic cancer assessed by \u03b1v\u03b26-integrin PET\/CT using 68Ga- Trivehexin: incidental detection of a brain metastasis. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06750-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2232_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091504","volume":"17","author":"L Urso","year":"2025","unstructured":"Urso L, Napolitano R, Speltri G, Tuncel M, Badrane I, Uccelli L, et al. 68Ga-Trivehexin: current status of \u03b1v\u03b26-integrin imaging and perspectives. Cancers (Basel). 2025;17(9):1504. https:\/\/doi.org\/10.3390\/cancers17091504. (PMID: 40361431; PMCID: PMC12071049).","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2232_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1097\/MNM.0000000000000899","volume":"39","author":"M Araz","year":"2018","unstructured":"Araz M, Soydal \u00c7, \u00d6zkan E, Kir MK, \u0130bi\u015f E, G\u00fcll\u00fc S, et al. The efficacy of fluorine-18-choline PET\/CT in comparison with 99mTc-MIBI SPECT\/CT in the localization of a hyperfunctioning parathyroid gland in primary hyperparathyroidism. Nucl Med Commun. 2018;39(11):989\u201394.","journal-title":"Nucl Med Commun"},{"issue":"13","key":"2232_CR10","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1007\/s00259-024-06846-z","volume":"51","author":"S Kuyumcu","year":"2024","unstructured":"Kuyumcu S, Denizmen D, Has-Simsek D, Poyanli A, Uzum AK, Buyukkaya F, et al. 68Ga- Trivehexin PET\/CT: a promising novel tracer for primary hyperparathyroidism. Eur J Nucl Med Mol Imaging. 2024;51(13):3912\u201323. https:\/\/doi.org\/10.1007\/s00259-024-06846-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"2232_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/life15121861","volume":"15","author":"P Petranovi\u0107 Ov\u010dari\u010dek","year":"2025","unstructured":"Petranovi\u0107 Ov\u010dari\u010dek P, Giovanella L, Tuncel M, Inukai JI, Liberini V, Romi\u0107 M, et al. Molecular imaging in parathyroid carcinoma management: a comprehensive review. Life (Basel). 2025;15(12):1861. https:\/\/doi.org\/10.3390\/life15121861. (PMID: 41465801; PMCID: PMC12734229).","journal-title":"Life (Basel)"},{"issue":"7","key":"2232_CR12","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1097\/RLU.0000000000005735","volume":"50","author":"D Denizmen Zorba","year":"2025","unstructured":"Denizmen Zorba D, Kuyumcu S, Kubat Uzum A, Isik EG, Sanli Y. Detection of recurrent parathyroid cancer using 68 Ga-Trivehexin PET\/CT. Clin Nucl Med. 2025;50(7):e451\u20132. https:\/\/doi.org\/10.1097\/RLU.0000000000005735. (Epub 2025 May 15. PMID: 40369809).","journal-title":"Clin Nucl Med"},{"issue":"1","key":"2232_CR13","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1097\/RLU.0000000000005989","volume":"51","author":"S Kar","year":"2026","unstructured":"Kar S, Lele VR, Shaikh N. 68 Ga-Trivehexin uptake in brown tumors in hyperparathyroidism: a novel finding. Clin Nucl Med. 2026;51(1):e46\u20137 (Epub 2025 May 19. PMID: 40392150).","journal-title":"Clin Nucl Med"},{"key":"2232_CR14","doi-asserted-by":"crossref","unstructured":"Kumar SA, S S, Goyal H, Madivanane V, Ponnusamy M, Halanaik D. \"Metabolic Superscan\" Pattern in a Case of Secondary Hyperparathyroidism With Parathyroid Hyperplasia Detected on 68 Ga- Trivehexin PET\/ CT. Clin Nucl Med. 2025;16 10. (Epub ahead of print: PMID: 41428407).","DOI":"10.1097\/RLU.0000000000006255"},{"issue":"8","key":"2232_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14082029","volume":"14","author":"J Benjamin","year":"2022","unstructured":"Benjamin J, Maillard L, Morelec I, Got P, Borson-Chazot F, Lifante JC. Diagnostic performance of 18F-Choline positron emission tomography\/contrast-enhanced computed tomography in adenoma detection in primary hyperparathyroidism after inconclusive imaging: a retrospective study of 215 patients. Cancers (Basel). 2022;14(8):2029. https:\/\/doi.org\/10.3390\/cancers14082029. (PMID: 35454936; PMCID: PMC9028950).","journal-title":"Cancers (Basel)"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02232-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02232-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02232-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:43:38Z","timestamp":1787665418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02232-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2232"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02232-x","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}